Address
1055 Westlakes Drive
Malvern, PA 19312
United States of America (the)
Phone
610 727 3913
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
January 29, 2020
| Name | Title | Pay | Year Born |
| Maria L. Maccecchini | Founder, Acting CFO, CEO, President & Executive Director | 808,000 | 1951 |
| Eve Damiano | Senior Vice President of Regulatory Operations | 0 | N/A |
| Hilda Maibach | Senior Vice President of Statistics | 0 | N/A |
| Blake Jensen | Head of Quality | 0 | N/A |
| Cheng Fang | Senior Vice President of Research & Development | 0 | N/A |
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.